Based on the latest scientific data, there is a new pharmacological therapy available in Indonesia for the management of Helicobacter pylori infection: Vonoprazan. Vonoprazan is a novel Potassium-Competitive Acid Blocker (P-CAB) that can replace the role of Proton Pump Inhibitors (PPIs) in eradicating H. pylori and has shown superior benefits compared to PPIs.

This new therapy is anticipated to provide an alternative treatment option for H. pylori cases. Consequently, the Central Board of the Indonesian Gastroenterology Association (PB PGI) has conducted a review of Potassium-Competitive Acid Blockers (P-CAB) through the Addendum to the National Consensus on the Management of Dyspepsia and Helicobacter Pylori Infection in Indonesia 2024. This addendum is based on recent similar consensus guidelines and evidence-based medicine from various global medical centers, and aims to serve as a reference for doctors in Indonesia for managing H. pylori cases in daily practice.

The addendum was discussed on February 18, 2024, via Zoom meeting. The event was attended by 34 panelists, including advisors and members of the Central Board of PB PGI, as well as chairpersons from the PPHI-PEGI-PGI branch offices across Indonesia.

We hope this addendum will serve as a guide for doctors, including general practitioners, internal medicine specialists, and gastroenterohepatology consultants, to enhance patient care.